SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
January 04, 2024 07:18 ET
|
SciSparc Ltd
The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of...
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
January 25, 2023 08:30 ET
|
Clearmind Medicine Inc.
Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug candidate MEAI from attendees at one of the...
SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.
June 07, 2022 08:30 ET
|
SciSparc Ltd
TEL AVIV, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment
June 07, 2022 08:30 ET
|
Clearmind Medicine Inc.
The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment
June 02, 2022 07:48 ET
|
Clearmind Medicine Inc.
No dedicated treatment currently available for cocaine addiction VANCOUVER, June 02, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the...
Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder
May 26, 2022 09:30 ET
|
Clearmind Medicine Inc.
Clearmind aims to initiate clinical trials with CMND-100 by year’s end VANCOUVER, May 26, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF,FSE: CWY0) (“Clearmind” or the...
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
May 24, 2022 08:30 ET
|
Clearmind Medicine Inc.
Pre-clinical trial based on the proprietary combination demonstrates high safety profile in addition to a significant suppressive effect on alcohol consumption Vancouver, May 24, 2022 ...
SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
May 24, 2022 08:30 ET
|
SciSparc Ltd
Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption TEL AVIV, Israel, May 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
May 19, 2022 08:15 ET
|
Clearmind Medicine Inc.
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER, May 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Announces Pre-IND Meeting Date with FDA
May 13, 2022 09:30 ET
|
Clearmind Medicine Inc.
Clearmind aims to initiate clinical trials with CMND-100 by year’s end Vancouver, May 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or...